June 10, 2017 : Issue #889

• GLP-1 Agonist Has CV Benefits
• Can Diet Drinks Increase Calorie Intake?
• Degludec Versus Glargine: Evaluating Differences in Glycemic Variabilities and Patient Satisfaction
• Associated Risk Factors in the Development of Bulimia Symptoms in Adolescents with Type 1 Diabetes
• Prospective Studies May Decrease the Incidence of DKA in Type 1 Diabetes in Children
• Severe Hypoglycemia: Does the Risk Increase or Decrease with Longer Type 1 Diabetes Duration?
• Current Video Interview: Dr. Matthew Weir on the Pros and Cons of SGLT-2s

This week marks the start of the diabetes research reporting season, as the ADA Scientific Sessions began yesterday in San Diego. This is the number 1 go-to conference for new research and products focused on improving patient care. Our Medical  Editor, Joy Pape, and Publisher, Steve Freed, are there to get all the information for those of us who can’t attend. They have lined up over 30 interviews with key researchers and companies to bring you the inside scoop. In addition, our current Intern, Joanna Martinez-Mendez, has been able to get some insights from some thought leaders who won’t be able to attend, and she has prepared a series of articles for this week’s newsletter, so be sure you check them out.

*****************************

We can make a difference!

*****************************

Dave Joffe

Editor-in-chief

Approximately what percentage of type 2 patients do you have on SGLT-2 Inhibitors?
1. None
2. 5%
3. 10%
4. 15%
5. 20% or greater

Follow the link to see how you and your colleagues compare!

The Forum for Injection Technique (FIT) UK provides evidence-based best practice recommendations for people with diabetes who are using injectable therapies and for clinicians who care for people with diabetes using injectable therapies. Through these recommendations, people with diabetes can achieve the best possible health outcomes by ensuring that the correct dose of medication is delivered to the correct injection site, using the correct technique. FIT UK understands that written guidelines alone will not change clinical practice unless appropriately implemented.  Download the FIT UK for Injection Technique.

Diabetes in Control speaks with top endocrinologists and other medical professionals to bring you the latest in diabetes news and research. This week, we have a special interview with one of the presenters at the AACE 26th Annual Scientific & Clinical Congress in Austin, Texas. Dr. Weir discusses the pros and cons of SGLT-2 inhibitors in clinical practice.

According to the Centers for Disease Control and Prevention, what percentage of patients who have diabetes and are older than 65 years old will die of heart disease?
A. 58%
B. 68%
C. 78%
D. 88%

Follow the link to see the correct answer.

The authors of this study investigated whether short sleep duration affects the impact of metabolic syndrome (MetS) on mortality. During the study, 1,344 participants (mean age, 48.8 years) were followed for an average of 16.6 years. The participants were classified into two groups based on polysomnographic (sleep study) sleep duration into ≥6 hours or <6 hours sleep. During follow-up, 22% of participants died. All-cause and cardiovascular disease/cerebrovascular mortality associated with MetS hazard ratios (95% CI) were 1.29 (0.89–1.87) and 1.49 (0.75–2.97) for individuals who slept ≥6 hours and 1.99 (1.53–2.59) and 2.10 (1.39–3.16) for individuals who slept <6 hours. This effect was mainly a result of elevated blood pressure and glucose dysregulation among patients with MetS. The risk of mortality associated with MetS is increased in those with a sleep duration of <6 hours. Published in Diabetes, June 01, 2017

New study shows lower risk for poor cardiovascular outcomes for T2 patients on glucagonlike peptide-1 receptor agonists.

Recent studies focus on increase in hunger, conclude diet drinks possibly cause an increase in blood sugars.

One long-acting insulin may be better at controlling glycemic variations.

In addition to psychosocial risk factors, disease related factors may also be contributing to bulimic symptoms.

Placing newborns in prospective studies to conduct genetic screenings with follow up may reduce the risk of DKA at diagnosis of type 1.

After 30 years of follow-up studies, DCCT/EDIC study gives findings regarding risk of severe hypoglycemia.

Quote of the Week!

“Sleep is that golden chain that ties health and our bodies together.”

…Thomas Dekker

Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this week’s newsletter:

Joanna Martinez-Mendez, Lake Erie College of Osteopathic Medicine FL Campus, School of Pharmacy

Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
810 Bear Tavern Road Suite 102
Ewing, NJ, 08628
USA
www.diabetesincontrol.com